143 related articles for article (PubMed ID: 7951008)
21. Design and analysis issues for economic analysis alongside clinical trials.
Marshall DA; Hux M
Med Care; 2009 Jul; 47(7 Suppl 1):S14-20. PubMed ID: 19536012
[TBL] [Abstract][Full Text] [Related]
22. Economic analysis of a phase III study of G-CSF vs placebo following allogeneic blood stem cell transplantation.
Stinson TJ; Adams JR; Bishop MR; Kruse S; Tarantolo S; Bennet CL
Bone Marrow Transplant; 2000 Sep; 26(6):663-6. PubMed ID: 11041569
[TBL] [Abstract][Full Text] [Related]
23. Which cancer clinical trials should be considered for economic evaluation? Selection criteria from the National Cancer Institute of Canada's Working Group on Economic Analysis.
Evans WK; Coyle D; Gafni A; Walker H;
Chronic Dis Can; 2003; 24(4):102-7. PubMed ID: 14733759
[TBL] [Abstract][Full Text] [Related]
24. Engraftment syndrome after autologous hematopoietic stem cell transplant supported by granulocyte-colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor (GM-CSF).
Akasheh M; Eastwood D; Vesole DH
Bone Marrow Transplant; 2003 Jan; 31(2):113-6. PubMed ID: 12621492
[TBL] [Abstract][Full Text] [Related]
25. PIXY321 (GM-CSF/IL-3 fusion protein): biology and early clinical development.
Vadhan-Raj S
Stem Cells; 1994 May; 12(3):253-61. PubMed ID: 8075592
[TBL] [Abstract][Full Text] [Related]
26. Cost effectiveness of myeloid growth factors in cancer chemotherapy.
Lyman GH; Kuderer NM
Curr Hematol Rep; 2003 Nov; 2(6):471-9. PubMed ID: 14561391
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
[TBL] [Abstract][Full Text] [Related]
28. Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation.
Bennett C; Waters T; Stinson T; Almagor O; Pavletic Z; Tarantolo S; Bishop M
Bone Marrow Transplant; 1999 Sep; 24(5):555-60. PubMed ID: 10482942
[TBL] [Abstract][Full Text] [Related]
29. Role of hematopoietic growth factors in transfusion medicine.
Goodnough LT
Curr Opin Hematol; 1994 Nov; 1(6):462-70. PubMed ID: 9371324
[TBL] [Abstract][Full Text] [Related]
30. Economic analyses of phase III cooperative cancer group clinical trials: are they feasible?
Bennett CL; Golub R; Waters TM; Tallman MS; Rowe JM
Cancer Invest; 1997; 15(3):227-36. PubMed ID: 9171857
[TBL] [Abstract][Full Text] [Related]
31. Economic analysis alongside clinical trials: problems and potential.
Drummond M
J Rheumatol; 1995 Jul; 22(7):1403-7. PubMed ID: 7562785
[TBL] [Abstract][Full Text] [Related]
32. Free-riding and the prisoner's dilemma: problems in funding economic analyses of phase III cancer clinical trials.
Bennett CL; Smith TJ; George SL; Hillner BE; Fleishman S; Niell HB
J Clin Oncol; 1995 Sep; 13(9):2457-63. PubMed ID: 7545222
[TBL] [Abstract][Full Text] [Related]
33. Economic analysis in phase III clinical cancer trials.
Bennett CL; Armitage JL; Buchner D; Gulati S
Cancer Invest; 1994; 12(3):336-42. PubMed ID: 8187012
[TBL] [Abstract][Full Text] [Related]
34. Clinical relevance of granulocyte-macrophage colony-stimulating factor.
Engelhard M; Brittinger G
Semin Oncol; 1994 Dec; 21(6 Suppl 16):1-4. PubMed ID: 7801142
[No Abstract] [Full Text] [Related]
35. Introduction to clinical economics: assessment of cancer therapies.
Schulman KA; Glick HA; Yabroff KR; Eisenberg JM
J Natl Cancer Inst Monogr; 1995; (19):1-9. PubMed ID: 7577196
[TBL] [Abstract][Full Text] [Related]
36. [Policies for clinical trials in cancer].
Suemasu K
Gan No Rinsho; 1988 Jan; 34(1):7-12. PubMed ID: 3339851
[TBL] [Abstract][Full Text] [Related]
37. Economic analyses in clinical trials for cooperative groups: operational considerations.
Bennett CL; Waters TM
Cancer Invest; 1997; 15(5):448-53. PubMed ID: 9316627
[TBL] [Abstract][Full Text] [Related]
38. Special issues that arise in applying techniques of economic analysis to evaluation of cancer therapies.
Weeks JC
J Natl Cancer Inst Monogr; 1995; (19):11-2. PubMed ID: 7577197
[TBL] [Abstract][Full Text] [Related]
39. Hematopoietic growth factors. Defining the appropriate clinical role in multimodality cancer therapy.
Demetri GD
Chest; 1995 Jun; 107(6 Suppl):255S-260S. PubMed ID: 7540124
[TBL] [Abstract][Full Text] [Related]
40. A progress report on reimbursement of biotherapy: prospects for the 1990s.
Yasko JM
Oncol Nurs Forum; 1989; 16(6 Suppl):42-7. PubMed ID: 2687813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
